Tocagen (NASDAQ:TOCA) released its quarterly earnings results on Thursday. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.22, Morningstar.com reports. Tocagen had a negative return on equity of 77.46% and a negative net margin of 130,944.75%. The firm had revenue of $18.01 million for the quarter, compared to analyst estimates of $2.01 million.
TOCA traded up $0.78 during trading on Friday, reaching $13.08. The company’s stock had a trading volume of 184,495 shares, compared to its average volume of 165,769. Tocagen has a 52-week low of $7.52 and a 52-week high of $15.80. The firm has a market capitalization of $240.61 million, a PE ratio of -4.92 and a beta of 2.84. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 0.56.
A number of brokerages have weighed in on TOCA. Zacks Investment Research raised Tocagen from a “sell” rating to a “hold” rating in a report on Saturday. ValuEngine raised Tocagen from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. BidaskClub lowered Tocagen from a “buy” rating to a “hold” rating in a report on Friday, October 5th. B. Riley lifted their price objective on Tocagen from $15.00 to $22.00 and gave the company a “buy” rating in a report on Thursday, September 20th. Finally, Chardan Capital began coverage on Tocagen in a report on Thursday, August 30th. They issued a “buy” rating and a $30.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Tocagen currently has an average rating of “Buy” and a consensus price target of $20.75.
Tocagen Company Profile
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Further Reading: Return on Investment (ROI)
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.